<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149053">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01159951</url>
  </required_header>
  <id_info>
    <org_study_id>112263</org_study_id>
    <nct_id>NCT01159951</nct_id>
  </id_info>
  <brief_title>Analysis of Trends Over Time of Hepatitis Related Incidence in Panama</brief_title>
  <official_title>Time Trend Analysis of the Incidence of Hepatitis- Related Outcomes (Viral Hepatitis A and Unspecified Viral Hepatitis) Reported to the Surveillance System of Panama, 2000-2010</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to analyze the incidence of baseline hepatitis related outcomes
      (viral hepatitis A and unspecified viral hepatitis) together with the current frequency of
      the same outcome after introduction of Havrix™ in Panama.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, systematic review of the databases of epidemiologic surveillance system
      (Ministry of Health), for hepatitis related outcomes will be performed. The analysis will be
      performed by age group, years and country region.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of reported hepatitis related outcomes (viral hepatitis A and unspecified viral hepatitis)</measure>
    <time_frame>In post vaccine introduction period (2008-2010) compared to pre-vaccination period (2000-2007)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of hepatitis related outcomes (viral hepatitis A and unspecified viral hepatitis) by year</measure>
    <time_frame>From year 2000 until year 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of hepatitis related outcomes (viral hepatitis A and unspecified viral hepatitis) by age groups</measure>
    <time_frame>From year 2000 until year 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of hepatitis related outcomes (viral hepatitis A and unspecified viral hepatitis) by region</measure>
    <time_frame>From year 2000 until year 2010</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1</enrollment>
  <condition>Hepatitis</condition>
  <arm_group>
    <arm_group_label>Hepatitis Cohort</arm_group_label>
    <description>Subjects suffering with hepatitis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Epidemiologic Surveillance System of the Ministry of Health of Panama</intervention_name>
    <description>Systematic review of the databases of epidemiologic surveillance system, Ministry of health, Panama</description>
    <arm_group_label>Hepatitis Cohort</arm_group_label>
  </intervention>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      No samples retained
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The target population to be studied will be all subjects reported with hepatitis related
        outcomes to the Epidemiologic Surveillance System of the Ministry of Health of Panama,
        between 2000 and 2010.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hepatitis related outcomes occurred during the period analyzed and registered in the
             Epidemiologic Surveillance System of the Ministry of Health, will be collected for
             the study

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Clayton</city>
        <state>Panamá</state>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Panama</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <lastchanged_date>November 10, 2011</lastchanged_date>
  <firstreceived_date>July 8, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Cheri Hudson; Clinical Disclosure Advisor</name_title>
    <organization>GSK Clinical Disclosure</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
